Journal September 16, 2026 6 min read

How to Reconstitute GHRP-6: A Laboratory Research Guide

GHRP-6 is a synthetic hexapeptide ghrelin receptor agonist. This guide covers its identity, receptor pharmacology, and the preclinical models in which it has been studied, with all findings attributed to their original r

peptides-pro Editorial

GHRP-6, formally growth hormone-releasing peptide-6 (also written growth hormone releasing protein-6), is a synthetic six-amino-acid ghrelin analog and growth hormone secretagogue. It is supplied as a lyophilized powder for laboratory research and is reconstituted with a suitable solvent before use in in vitro or animal studies. The evidence block does not provide its sequence, molecular formula, or molecular weight, so those identifiers are not stated here. The work reviewed below centres on the growth hormone secretagogue receptor (GHSR), the ghrelin receptor through which GHRP-6 acts [3][5].

Reconstitution is a laboratory procedure: the lyophilized peptide is dissolved in a compatible solvent to produce a stock solution of known concentration, which is then diluted into the experimental medium or vehicle. Because the evidence block does not specify a solvent, a concentration, or a storage condition for GHRP-6, no such values are given here. What the evidence does support is a body of preclinical work in rats, fish, chickens, and human oocytes, summarised below.

Research Studies

GHRP-6 and post-infarct ventricular remodelling in rats

In a permanent coronary ligation model, rats were assigned to sham-operated, infarcted plus saline, or infarcted plus GHRP-6 groups, with treatment beginning after surgery and continuing for seven days. The authors had previously identified 0.4 mg/kg as the minimum effective dose for enhancing inotropy by echocardiographic parameters in healthy rats. In the infarct model, GHRP-6 was reported to ameliorate post-infarct ventricular remodelling and systolic dysfunction [1]. This is an animal model; no human cardiac data are presented in the evidence block.

GHRP-6 and endocrine and immune responses in Sparus aurata

GHRP-6 was included in aquafeed at 500 µg/kg of feed and fed to gilthead sea bream (Sparus aurata) for 97 days, after which fish received an intraperitoneal injection of saline or Incomplete Freund's adjuvant (IFA) at 100 µL per 100 g fish. The study assessed endocrine and immune responses following IFA treatment and reported that the ghrelin analog modulated those responses [2]. This is a fish model.

GHRP-6 and locomotor activity during acute nicotine withdrawal in rats

Male and female Wistar rats received intraperitoneal nicotine at 2 mg/kg or saline twice daily for seven days, then underwent acute nicotine withdrawal. Ghrelin and GHRP-6 were tested for effects on horizontal and vertical activity, and changes in locomotor activity observed during withdrawal were reported to be attenuated by both peptides [3]. This is a rat model.

GHRP-6 and food intake in broiler chickens

In a series of four intracerebroventricular experiments in broiler chickens, LEAP-2 was injected at 0.75, 1.5, or 3 nmol, and the interaction with cannabinoid and ghrelin systems was examined. One experiment used the ghrelin receptor antagonist (D-Lys-3)-GHRP-6 at 0.5 nmol [6]. This is an avian model, and the section reports the experimental design rather than a human outcome.

GHRP-6 and human oocyte maturation in vitro

In an experimental in vitro maturation (IVM) study, 240 human germinal vesicle (GV) oocytes were cultured in varying concentrations of GHRP-6, and maturation rates were assessed [7]. This is an in vitro study using human oocytes; it does not establish any effect in a living human subject.

GHRP-6 and the ghrelin-dopamine cascade in Flinders Sensitive Line rats

A novel butyrylcholinesterase inhibitor was evaluated in the Flinders Sensitive Line rat model of major depressive disorder, with behavioural assessments including the forced swim test, sucrose preference test, and novel object recognition test. The study examined the role of the ghrelin-dopamine cascade, a pathway in which GHRP-6 acts as a ghrelin receptor agonist [8]. This is a rat model of depression.

GHRP-6 in acute lung injury and interstitial fibrosis

In lipopolysaccharide- and zymosan-induced lung injury biomodels, GHRP-6 was reported to ameliorate acute lung injury and its subsequent evolution to interstitial fibrosis [9]. This is an animal model.

GHRP-6 hydrogel in acute kidney injury

A GHRP-6 hydrogel was studied for acute kidney injury therapy via metabolic regulation, with attention to renal tubular epithelial cells and the metabolic reprogramming that determines functional recovery versus fibrosis [10]. This is a preclinical model.

GHRP-6 and nervous necrosis virus in fish

GHRP-6, described as a six-amino-acid synthetic peptide acting as a ghrelin analog with growth-promoting and immunomodulatory activity in several fish species, was evaluated against nervous necrosis virus (NNV) infection [11]. This is a fish model.

Ghrelin and embryo development after ovarian hyperstimulation

Controlled ovarian hyperstimulation (COH) has been associated with reduced reproductive success, and prior work demonstrated that COH increases circulating ghrelin. The study examined ghrelin's role in COH-induced alterations and reported that ghrelin impairs embryo development after ovarian hyperstimulation [12]. This is a preclinical reproductive model.

GHRP-6 in the GH-IGF-1 axis literature

A review of performance-enhancing peptides marketed as research compounds places GHRP-6 among growth hormone secretagogues, alongside GHRP-2, hexarelin, and ipamorelin, and notes that such peptides are intended to modulate the GH-IGF-1 axis [5]. This is a review; it does not report a primary experimental result for GHRP-6.

GHRP-6 and a clinical case of osteophytic dysphagia

A case report described a 62-year-old male ex-military recreational bodybuilder with cervicalgia and left shoulder pain, in whom imaging showed multilevel degenerative changes including a prominent anterior osteophyte at C3-C4 with esophageal compression, and who reported intermittent dysphagia with larger food boluses. He reported a cervical injury during jiu-jitsu and was a long-term growth hormone user [4]. This is a single case report; it does not establish causation for any compound.

If you are reading this for personal health reasons

The material described here is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.